Skip to main content

Table 1 Distribution of SCCmec types according to antibiotic non-susceptibility phenotypes for MRSA isolates (n = 2019)

From: Diversity of SCCmec elements and spa types in South African Staphylococcus aureus mecA-positive blood culture isolates

Antibiotic non-susceptibility phenotype SCCmec type
I II III IV V VI Untypeable Negative
Erythromycin 0 133 (6.58%) 920 (45.56%) 391 (19.36%) 4 (0.19%) 2 (0.09%) 249 (12.33%) 2 (0.09%)
Clindamycin 1 (0.04%) 129 (6.38%) 106 (5.25%) 31 (1.53%) 0 4 (0.19%) 30 (1.48%) 0
Oxacillin 2 (0.09%) 135 (6.68%) 916 (45.36%) 648 (32.09%) 7 (0.34%) 9 (0.44%) 271 (13.42%) 2 (0.09%)
Penicillin 2 (0.09%) 138 (6.83%) 926 (45.86%) 651 (32.24%) 7 (0.34%) 9 (0.44%) 274 (13.57%) 2 (0.09%)
Trimethoprim/Sulfamethoxazole 0 12 (0.59%) 883 (43.73%) 542 (26.84%) 2 (0.09%) 3 (0.14%) 42 (2.08%) 2 (0.09%)
Daptomycin 0 0 7 (0.34%) 2 (0.09%) 0 0 2 (0.09%) 0
Linezolid 0 3 (0.14%) 3 (0.14%) 3 (0.14%) 0 0 3 (0.14%) 0
Tetracycline 0 14 (0.69%) 913 (45.22%) 573 (28.38%) 3 (0.14%) 2 (0.09%) 79 (3.91%) 2 (0.09%)
Rifampin 0 14 (0.69%) 62 (3.07%) 571 (28.28%) 1 (0.04%) 2 (0.09%) 19 (0.94%) 2 (0.09%)
Ciprofloxacin 0 134 (6.63%) 917 (45.41%) 589 (29.17%) 4 (0.19%) 3 (0.14%) 76 (3.76%) 2 (0.09%)
Levofloxacin 0 134 (6.63%) 916 (45.36%) 512 (25.35%) 3 (0.14%) 3 (0.14%) 75 (3.71%) 2 (0.09%)
Moxyfloxacin 0 133 (6.58%) 918 (45.46%) 510 (25.26%) 3 (0.14%) 2 (0.09%) 75 (3.71%) 2 (0.09%)
Gentamicin 0 19 (0.94%) 912 (45.17%) 556 (27.53%) 6 (0.29%) 3 (0.14%) 242 (11.98%) 2 (0.09%)
  1. Susceptibility was classified according to CLSI guidelines [26]
  2. Suggested antibiotics approved by the US Food and Drug Administration (FDA) for clinical use were included in the table. Antibiotics excluded were azithromycin as erythromycin is a surrogate for macrolides, cefoxtin as oxacillin is included for MRSA, those that are recommended for urine only as well as those that were not tested for using the MicroScan Gram-positive PM-33 panel. In addition, vancomycin was excluded as all isolates were susceptible